Opthea (OPT) Competitors $3.41 +0.23 (+7.23%) As of 07/3/2025 02:20 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPT vs. NAMS, DNLI, KNSA, RXRX, APGE, CGON, AGIO, INDV, IRON, and BLTEShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), CG Oncology (CGON), Agios Pharmaceuticals (AGIO), Indivior (INDV), Disc Medicine (IRON), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Its Competitors NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Recursion Pharmaceuticals Apogee Therapeutics CG Oncology Agios Pharmaceuticals Indivior Disc Medicine Belite Bio NewAmsterdam Pharma (NASDAQ:NAMS) and Opthea (NASDAQ:OPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations. Which has more volatility & risk, NAMS or OPT? NewAmsterdam Pharma has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, Opthea has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Which has better valuation and earnings, NAMS or OPT? Opthea has lower revenue, but higher earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$47.14M47.26-$241.60M-$1.88-10.56Opthea$87.67K5,986.77-$220.24MN/AN/A Does the media favor NAMS or OPT? In the previous week, Opthea had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 3 mentions for Opthea and 0 mentions for NewAmsterdam Pharma. Opthea's average media sentiment score of 1.65 beat NewAmsterdam Pharma's score of 1.54 indicating that Opthea is being referred to more favorably in the news media. Company Overall Sentiment NewAmsterdam Pharma Very Positive Opthea Very Positive Do analysts rate NAMS or OPT? NewAmsterdam Pharma currently has a consensus price target of $42.89, indicating a potential upside of 116.12%. Opthea has a consensus price target of $1.33, indicating a potential downside of 60.90%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe NewAmsterdam Pharma is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17 Do institutionals & insiders have more ownership in NAMS or OPT? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 56.0% of Opthea shares are held by institutional investors. 20.8% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 3.2% of Opthea shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is NAMS or OPT more profitable? Opthea has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -397.45%. Opthea's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam Pharma-397.45% -37.34% -33.45% Opthea N/A N/A N/A SummaryOpthea beats NewAmsterdam Pharma on 9 of the 15 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.84M$2.89B$5.49B$9.01BDividend YieldN/A2.43%5.38%4.09%P/E RatioN/A21.5627.4220.26Price / Sales5,986.77245.52407.97121.21Price / CashN/A41.9536.6357.47Price / Book-6.097.518.085.67Net Income-$220.24M-$55.05M$3.16B$248.47M7 Day PerformanceN/A4.59%2.81%3.29%1 Month PerformanceN/A4.86%3.68%5.19%1 Year Performance80.42%5.82%35.29%21.35% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea0.562 of 5 stars$3.41+7.2%$1.33-60.9%+80.4%$524.84M$87.67K0.008News CoverageGap UpNAMSNewAmsterdam Pharma3.0736 of 5 stars$18.11-2.5%$42.89+136.8%-0.8%$2.08B$45.56M-9.634DNLIDenali Therapeutics4.535 of 5 stars$13.99-0.8%$33.71+141.0%-31.0%$2.05B$330.53M-5.24430KNSAKiniksa Pharmaceuticals International3.6932 of 5 stars$27.67-1.3%$38.80+40.2%+45.8%$2.05B$423.24M-110.68220RXRXRecursion Pharmaceuticals2.1303 of 5 stars$5.06+0.6%$7.00+38.3%-28.4%$2.04B$58.84M-2.86400Analyst ForecastAPGEApogee Therapeutics2.9022 of 5 stars$43.43+0.1%$94.60+117.8%+26.8%$2.00BN/A-12.0691News CoverageAnalyst ForecastInsider TradeHigh Trading VolumeCGONCG Oncology2.4153 of 5 stars$26.00+0.2%$58.67+125.6%-12.8%$1.98B$1.14M-17.2261AGIOAgios Pharmaceuticals4.0895 of 5 stars$33.26-0.6%$58.60+76.2%-14.2%$1.94B$36.50M2.96390Insider TradeINDVIndivior2.1141 of 5 stars$14.74+5.7%$17.00+15.3%+5.4%$1.92B$1.19B-47.551,051High Trading VolumeIRONDisc Medicine3.0961 of 5 stars$52.96-2.8%$96.70+82.6%+23.2%$1.89BN/A-13.5130Analyst ForecastBLTEBelite Bio2.5064 of 5 stars$57.70-2.3%$96.67+67.5%+30.6%$1.88BN/A-42.4310Analyst ForecastGap Up Related Companies and Tools Related Companies NAMS Alternatives DNLI Alternatives KNSA Alternatives RXRX Alternatives APGE Alternatives CGON Alternatives AGIO Alternatives INDV Alternatives IRON Alternatives BLTE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPT) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPT Stock Alerts